Regeneron Pharmaceuticals Inc. purchased a new position in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,254,827 shares of the company's stock, valued at approximately $3,689,000. 2seventy bio accounts for 0.3% of Regeneron Pharmaceuticals Inc.'s investment portfolio, making the stock its 3rd largest holding. Regeneron Pharmaceuticals Inc. owned 2.43% of 2seventy bio as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Erste Asset Management GmbH bought a new position in 2seventy bio during the third quarter worth $25,000. Rhumbline Advisers boosted its holdings in 2seventy bio by 9.5% in the fourth quarter. Rhumbline Advisers now owns 84,670 shares of the company's stock worth $249,000 after acquiring an additional 7,379 shares in the last quarter. XTX Topco Ltd boosted its holdings in 2seventy bio by 61.1% in the third quarter. XTX Topco Ltd now owns 24,416 shares of the company's stock worth $115,000 after acquiring an additional 9,257 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in 2seventy bio in the fourth quarter worth approximately $32,000. Finally, Readystate Asset Management LP bought a new position in 2seventy bio in the third quarter worth approximately $53,000. Institutional investors and hedge funds own 93.90% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of 2seventy bio in a report on Friday. Leerink Partners restated a "market perform" rating and issued a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, 2seventy bio has an average rating of "Hold" and an average target price of $6.83.
Read Our Latest Stock Analysis on 2seventy bio
2seventy bio Stock Up 76.8 %
2seventy bio stock traded up $2.15 during mid-day trading on Tuesday, reaching $4.95. 31,479,115 shares of the company's stock were exchanged, compared to its average volume of 973,605. The business's fifty day simple moving average is $2.60 and its 200 day simple moving average is $3.68. The firm has a market capitalization of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99.
2seventy bio Profile
(
Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Further Reading
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
